Powerful Intelligence for Dealmakers
The following sample deal entries offer an insight into the level of detail you can expect when subscribing to Current Agreements.
Quark has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial more
Merck, through an affiliate, will purchase all assets related to Insmed's follow-on biologics platform more
Endo will commence an all-cash tender offer to acquire 100 percent of the outstanding common stock of Penwest Pharmaceuticals for $5.00 per Penwest share or $144 million more
Signup to receive our free monthly Deals Update newsletter.